Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 0.60 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766081 | 0.85 | PDE5A (0.59) | PDE5ACNR1CNR2ACHECYP1A2 | |
| SCHEMBL7493020 | 0.84 | CYP2D6 (0.57) | PDE5ACNR1CNR2ACHECYP1A2 | |
| SCHEMBL7492370 | 0.82 | PDE5A (0.62) | PDE5ACNR1CNR2ACHECYP1A2 | |
| SCHEMBL7494310 | 0.76 | PDE5A (0.62) | PDE5ACYP1A2CYP2D6KDM4ECYP3A4 | |
| SCHEMBL4849350 | 0.75 | PDE5A (1.00) | PDE5ACNR1CNR2ACHECYP1A2 | |
| SCHEMBL4428683 | 0.73 | PDE5A (0.61) | PDE5ACNR1CNR2ACHECYP1A2 | |
| SCHEMBL5565271 | 0.72 | PDE5A (0.64) | PDE5ACNR1CNR2ACHECYP1A2 | |
| SCHEMBL3621787 | 0.71 | ALDH1A1 (0.67) | PDE5ACNR1CNR2ACHECYP1A2 | |
| SCHEMBL3073971 | 0.70 | PDE5A (0.85) | PDE5ACNR1CNR2ACHECYP1A2 | |
| SCHEMBL13865190 | 0.70 | CYP2D6 (0.57) | PDE5ACNR1CNR2ACHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562579-A1 | THERAPEUTIC DELIVERY OF CARBON MONOXIDE | Hemocorm Limited (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004045599-A1 | THERAPEUTIC DELIVERY OF CARBON MONOXIDE | HEMOCORM LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| US-6387942-B2 | PYRAZOLYL COMPOUND; ANTICOAGULANTS, ANTIPROLIFERATIVE AGENT | YUNG SHIN PHARMACEUTICAL IND. CO. LTD (TW) | 2002-05-14 | — | — | US | disclosed |
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2002-01-10 | — | — | US | disclosed |
| EP-1166785-A1 | Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation | Yung Shin Pharmeutical Ind. Co., Ltd. (TW) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004518-A1 | Method of treating disorders related to protease-activated receptors-induced cell activation | F2R, HPN, F2RL1 | PDE5A 3372/4885CNR1 184/4885CNR2 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.